🔎 Trials Near Me

Home › Acute Myeloid Leukemia › Minnesota › Minneapolis

Acute Myeloid Leukemia clinical trials in Minneapolis, MN

20 studies for Acute Myeloid Leukemia are looking for participants at sites in and around Minneapolis (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection

RecruitingObservational studyHealthy volunteers welcome
  • Abbott-Northwestern Hospital, Minneapolis
  • Hennepin County Medical Center, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
Ages 40 to 75 · All sexes · Updated Oct 2, 2026 · NCT05334069

Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial)

RecruitingPhase 2
  • Abbott-Northwestern Hospital, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
Ages 18 to 59 · All sexes · Updated Sep 28, 2026 · NCT05554393

MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial)

RecruitingPhase 2
  • Abbott-Northwestern Hospital, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
Ages 18 and older · All sexes · Updated Sep 25, 2026 · NCT05564390

A Study to Find the Highest Dose of Cedazuridine and Decitabine Combination With Filgrastim as a Treatment Option After Hematopoietic Stem Cell Transplant in Children With High-Risk Acute Myeloid Leukemia

RecruitingPhase 1
  • University of Minnesota/Masonic Cancer Center, Minneapolis
Up to age 21 · All sexes · Updated Sep 23, 2026 · NCT07012044

Venetoclax and HMA Treatment of Older and Unfit Adults With FLT3 Mutated Acute Myeloid Leukemia (AML) (A MyeloMATCH Treatment Trial)

RecruitingPhase 2
  • Abbott-Northwestern Hospital, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06317649

Comparing New Treatments for People With Newly Diagnosed Acute Myeloid Leukemia That Has an IDH2 Gene Change (A MyeloMATCH Treatment Trial)

RecruitingPhase 2
  • Abbott-Northwestern Hospital, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT06672146

Testing New Therapies for Patients With Acute Myeloid Leukemia Who Are Newly Diagnosed and Have Not Yet Started Treatment (A MyeloMATCH Treatment Trial)

RecruitingPhase 2
  • Abbott-Northwestern Hospital, Minneapolis
  • Park Nicollet Clinic - Saint Louis Park, Saint Louis Park · 5 mi away
Ages 18 to 59 · All sexes · Updated Sep 22, 2026 · NCT05554406

A Study to Compare Standard Chemotherapy to Therapy With CPX-351 and/or Gilteritinib for Patients With Newly Diagnosed AML With or Without FLT3 Mutations

RecruitingPhase 3
  • Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
  • University of Minnesota/Masonic Cancer Center, Minneapolis
6 Months – 21 Years · All sexes · Updated Sep 17, 2026 · NCT04293562

The Pediatric Acute Leukemia (PedAL) Screening Trial - A Study to Test Bone Marrow and Blood in Children With Leukemia That Has Come Back After Treatment or Is Difficult to Treat - A Leukemia & Lymphoma Society and Children's Oncology Group Study

RecruitingPhase 1/2
  • Children's Hospitals and Clinics of Minnesota - Minneapolis, Minneapolis
  • University of Minnesota/Masonic Cancer Center, Minneapolis
Up to age 22 · All sexes · Updated Aug 25, 2026 · NCT04726241

Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

RecruitingPhase 3
  • Masonic Cancer Center, Minneapolis
29 Days – 21 Years · All sexes · Updated Aug 24, 2026 · NCT05183035

Studies to Assess Ziftomenib in Combination With Ven+Aza or 7+3 in Patients With Untreated NPM1-m or KMT2A-r AML

RecruitingPhase 3
  • University of Minnesota, Minneapolis
Ages 18 and older · All sexes · Updated Aug 20, 2026 · NCT07007312

Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

RecruitingPhase 1/2
  • Masonic Cancer Center, Minneapolis
Ages 18 and older · All sexes · Updated Jul 22, 2026 · NCT07008638

HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML

RecruitingPhase 1
  • Masonic Cancer Center, Minneapolis
Ages 18 and older · All sexes · Updated Jul 14, 2026 · NCT06594445

Allo HSCT Using RIC and PTCy for Hematological Diseases

RecruitingPhase 2
  • Masonic Cancer Center at University of Minnesota, Minneapolis
Up to age 75 · All sexes · Updated Jul 6, 2026 · NCT05805605

Myeloablative Allo HSCT With Related or Unrelated Donor for Heme Disorders

RecruitingPhase 2
  • Masonic Cancer Center at University of Minnesota, Minneapolis
Up to age 60 · All sexes · Updated Jun 25, 2026 · NCT03314974

Adapt NK for High Risk Myeloid Diseases as Bridge to Allo HSCT

RecruitingPhase 1/2
  • Mark Juckett, MD, Minneapolis
Ages 18 and older · All sexes · Updated May 19, 2026 · NCT07591649

MT2025-35 Allogeneic Hematopoietic Stem Cell Transplantation Using Reduced Intensity Conditioning Treosulfan and Fludarabine, With Post-Transplant Cytoxan (PTCy) for the Treatment of Hematological Diseases

RecruitingPhase 2
  • Masonic Cancer Center at University of Minnesota, Minneapolis
Ages 2 to 75 · All sexes · Updated Apr 16, 2026 · NCT07493538

Backtracking Leukemia-Typical Somatic Mutations in Cord Blood

RecruitingObservational study
  • University of Minnesota/Masonic Cancer Center, Minneapolis
Up to age 25 · All sexes · Updated Apr 8, 2026 · NCT05014165

MT2021-08T Cell Receptor Alpha/Beta Depletion PBSC Transplantation for Heme Malignancies

RecruitingPhase 2
  • University of Minnesota Masonic Cancer Center, Minneapolis
Up to age 60 · All sexes · Updated Apr 6, 2026 · NCT05735717

A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML

RecruitingPhase 1
  • University of Minnesota, Minneapolis
Ages 18 and older · All sexes · Updated Mar 13, 2026 · NCT05735184

About Acute Myeloid Leukemia

Acute Myeloid Leukemia (AML) is a cancer of the white blood cells. AML usually gets worse quickly if it is not treated. Read more.

More about Acute Myeloid Leukemia on MedlinePlus

Acute Myeloid Leukemia trials in other cities

Other studies in Minneapolis

From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.